Glycoprotein YKL-40: A potential biomarker of disease activity in rheumatoid arthritis during intensive treatment with csDMARDs and infliximab. Evidence from the randomised controlled NEO-RACo trial

OBJECTIVE: YKL-40, a chitinase-like glycoprotein associated with inflammation and tissue remodeling, is produced by joint tissues and recognized as a candidate auto-antigen in rheumatoid arthritis (RA). In the present study, we investigated YKL-40 as a potential biomarker of disease activity in pati...

Descripción completa

Detalles Bibliográficos
Autores principales: Väänänen, Tuija, Vuolteenaho, Katriina, Kautiainen, Hannu, Nieminen, Riina, Möttönen, Timo, Hannonen, Pekka, Korpela, Markku, Kauppi, Markku J., Laiho, Kari, Kaipiainen-Seppänen, Oili, Luosujärvi, Riitta, Uusitalo, Tea, Uutela, Toini, Leirisalo-Repo, Marjatta, Moilanen, Eeva
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5571914/
https://www.ncbi.nlm.nih.gov/pubmed/28841649
http://dx.doi.org/10.1371/journal.pone.0183294

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5571914/
https://www.ncbi.nlm.nih.gov/pubmed/28841649
http://dx.doi.org/10.1371/journal.pone.0183294

Ejemplares similares